Transcend Capital Advisors’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.83M | Sell |
34,067
-14,486
| -30% | -$1.2M | 0.22% | 105 |
|
|
2025
Q1 | $3.94M | Sell |
48,553
-797
| -2% | -$64.6K | 0.28% | 79 |
|
|
2024
Q4 | $4.44M | Sell |
49,350
-1,484
| -3% | -$134K | 0.32% | 72 |
|
|
2024
Q3 | $5.02M | Sell |
50,834
-3,275
| -6% | -$324K | 0.34% | 68 |
|
|
2024
Q2 | $5.02M | Buy |
54,109
+3,774
| +7% | +$350K | 0.36% | 63 |
|
|
2024
Q1 | $4.78M | Buy |
50,335
+2,131
| +4% | +$202K | 0.38% | 59 |
|
|
2023
Q4 | $4.3M | Buy |
48,204
+16,605
| +53% | +$1.48M | 0.38% | 60 |
|
|
2023
Q3 | $2.31M | Buy |
31,599
+18,820
| +147% | +$1.37M | 0.22% | 102 |
|
|
2023
Q2 | $1.06M | Sell |
12,779
-26
| -0.2% | -$2.16K | 0.1% | 203 |
|
|
2023
Q1 | $976K | Sell |
12,805
-897
| -7% | -$68.4K | 0.1% | 201 |
|
|
2022
Q4 | $1.14M | Sell |
13,702
-4,945
| -27% | -$410K | 0.12% | 185 |
|
|
2022
Q3 | $1.48M | Buy |
18,647
+122
| +0.7% | +$9.68K | 0.16% | 143 |
|
|
2022
Q2 | $1.38M | Buy |
18,525
+3,442
| +23% | +$256K | 0.14% | 159 |
|
|
2022
Q1 | $1.36M | Sell |
15,083
-124
| -0.8% | -$11.1K | 0.12% | 182 |
|
|
2021
Q4 | $1.7M | Buy |
15,207
+10,262
| +208% | +$1.15M | 0.15% | 157 |
|
|
2021
Q3 | $613K | Buy |
+4,945
| New | +$613K | 0.05% | 271 |
|
|
2021
Q2 | – | Sell |
-6,265
| Closed | -$851K | – | 436 |
|
|
2021
Q1 | $851K | Buy |
6,265
+33
| +0.5% | +$4.48K | 0.1% | 201 |
|
|
2020
Q4 | $877K | Sell |
6,232
-1,438
| -19% | -$202K | 0.12% | 183 |
|
|
2020
Q3 | $855K | Buy |
+7,670
| New | +$855K | 0.16% | 132 |
|